Melatonergic drugs in development

Clinical Pharmacology: Advances and Applications

Volumn 6, Issue , 2014, Pages 127-137

  Carocci, Alessia ^a   Catalano, Alessia ^a   Sinicropi, Maria Stefania ^b  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Circadian rhythms; Melatonin; MT1 MT2 ligands

Indexed keywords

AGOMELATINE; BETA METHYL 6 CHLOROMELATONIN; M 3 C; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN RECEPTOR AGONIST; PIROMELATINE; RAMELTEON; S 23219 1; S 23478 1; TASIMELTEON; UCM 765; UNCLASSIFIED DRUG;

ALERTNESS; ANTIDEPRESSANT ACTIVITY; BEDTIME DOSAGE; BINDING AFFINITY; DEPRESSION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BINDING SITE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; INCIDENCE; INSOMNIA; LIPOPHILICITY; MEMORY; MIGRAINE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); REM SLEEP; REVIEW; SLEEP DISORDER; SLEEP QUALITY; SLEEP TIME; SLEEP WAKING CYCLE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANQUILIZING ACTIVITY; TREATMENT RESPONSE;

EID: 84907693084     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S36600     Document Type: Review

References (120)

1. Lerner AB, Case JD, Takahashi Y, Lee TH, Mori W. Isolation of melatonin, the pineal factor that lightens melanocytes. J Am Chem Soc. 1958;80:2587–2587.
2. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev. 1991;12(2):151–180.
3. Cardinali DP, Rosner JM. Metabolism of serotonin by the rat retina in vitro. J Neurochem. 1971;18(9):1769–1770.
4. Tosini G, Menaker M. The clock in the mouse retina: melatonin synthesis and photoreceptor degeneration. Brain Res. 1998;789(2):221–228.
5. Carrillo-Vico A, Calvo JR, Abreu P, et al. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine and/or paracrine substance. FASEB J. 2004;18(3):537–539.
6. Raikhlin NT, Kvetnoy IM. Melatonin and enterochromaffine cells. Acta Histochem. 1976;55(1):19–24.
7. Bubenik GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci. 2002;47(10):2336–2348.
8. Klein DC. Arylalkylamine N-acetyltransferase: “the Timezyme”. J Biol Chem. 2007;282(7):4233–4237.
9. Berson DM, Dunn FA, Takao M. Phototransduction by retinal ganglion cells that set the circadian clock. Science. 2002;295(5557):1070–1073.
10. Sugden D. Melatonin biosynthesis in the mammalian pineal gland. Experientia. 1989;45(10):922–932.
11. Pevet P, Bothorel B, Slotten H, Saboureau M. The chronobiotic properties of melatonin. Cell Tissue Res. 2002;309(1):183–191.
12. Sewerynek E. Melatonin and the cardiovascular system. Neuro Endocrinol Lett. 2002;23 Suppl 1:79–83.
13. Carrillo-Vico A, Reiter RJ, Lardone PJ, et al. The modulatory role of melatonin on immune responsiveness. Curr Opin Investig Drugs. 2006;7(5):423–431.
14. Barrenetxe J, Delagrange P, Martinexz JA. Physiological and metabolic functions of melatonin. J Physiol Biochem. 2004;60(1):61–72.
15. Genovese T1, Di Paola R, Mazzon E, Muià C, Caputi AP, Cuzzocrea S. Melatonin limits lung injury in bleomycin treated mice. J Pineal Res. 2005;38(2):198–208.
16. Peres MF. Melatonin, the pineal gland and their implications for headache disorders. Chephalalgia. 2005;25(6):403–411.
17. Srinivasan V, Pandi-Perumal SR, Spence DW, et al. Potential use of melatonergic drugs in analgesia: mechanisms of action. Brain Res Bull. 2010;81(4–5):362–371.
18. Srinivasan V, Pandi-Perumal SR, Cardinali DP, Poeggeler B, Hardeland R. Melatonin in Alzheimer’s disease and other neurodegenerative disorders. Behav Brain Funct. 2006;2:15.
19. Medeiros CA, Carvalhedo de Bruin PF, Lopes LA, Magalhães MC, de Lourdes Seabra M, de Bruin VM. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson’s disease. A randomized, double blind, placebo-controlled study. J Neurol. 2007;254(4): 459–464.
20. Sofic E, Rimpapa Z, Kundurovic Z, et al. Antioxidant capacity of the neurohormone melatonin. J Neural Transm. 2005;112(3):349–358.
21. Reiter RJ, Paredes SD, Manchester LC, Tan DX. Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol. 2009;44(4):175–200.
22. Grant SG, Melan MA, Latimer JJ, Witt-Enderby PA. Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives. Expert Rev Mol Med. 2009;11:e5.
23. Davis VL, Dodda BR, Witt-Enderby PA. The prevention and treatment of breast cancer using melatonin. In: Watson, R, editor. Melatonin in the Promotion of Health. 2nd ed. Abingdon, UK: Taylor and Francis; 2011. p. 271–286.
24. Karamitri A1, Renault N, Clement N, Guillaume JL, Jockers R. Minireview: Toward the establishment of a link between melatonin and glucose homeostasis: association of melatonin MT2 receptor variants with type 2 diabetes. Mol Endocrinol. 2013;27(8):1217–1233.
25. Witt-Enderby PA, Clafshenkel WP, Kotlarczyk MP, Sethi S. Melatonin in bone health. In: Watson, R, editor. Melatonin in the Promotion of Health. 2nd ed. Abingdon, UK: Taylor and Francis; 2011. p. 261–270.
26. Maria S, Witt-Enderby PA. Melatonin effects on bone: potential use for the prevention and treatment for osteopenia, osteoporosis, and periodontal disease and for use in bone-grafting procedures. J Pineal Res. 2014;56(2):115–125.
27. Carocci A, Sinicropi MS, Catalano A, Lauria G, Genchi G. Melatonin in Parkinson’s Disease. In: Rana QA, editor. A Synopsis of Parkinson’s Disease. Intech; 2014.
28. Reppert SM, Weaver DR, Godson C. Melatonin receptors step into the light: Cloning and classification of subtypes. Trends Pharmacol Sci. 1996;17(3):100–102.
29. Von Gall C, Stehle JH, Weaver DR. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res. 2002;309(1):151–162.
30. Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem. 2002;2(2):113–132.
31. Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gusella JF. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci U S A. 1995;92(19):8734–8738.
32. Reppert SM. Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. J Biol Rhythms. 1997;12(6):528–531.
33. Dubocovich ML, Yun K, Al-Ghoul WM, Benloucif S, Masana MI. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J. 1998;12(12): 1211–1220.
34. Liu C, Weaver DR, Jin X, et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron. 1997;19(1):91–102.
35. Hunt AE, Al-Ghoul WM, Gillette MU, Dubocovich ML. Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol Cell Physiol. 2001;280(1): C110–C118.
36. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005;27(2):101–110.
37. Comai S, Gobbi B. Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology. J Psych Neurosci. 2014;39(1):6–21.
38. Doolen S, Krause DN, Dubocovich ML, Duckles SP. Melatonin mediates two distinct responses in vascular smooth muscle. Eur J Pharmacol. 1998;345(1):67–69.
39. Nosjean O, Ferro M, Cogé F, et al. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem. 2000;275(4): 31311–31317.
40. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J. 1993; 1(4):57–60.
41. Rodriguez C, Mayo JC, Sainz RM, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004;36(1):1–9.
42. Tomas-Zapico C, Coto-Montes A. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J Pineal Res. 2005;39(2):99–104.
43. Romero MP, Garcia-Perganeda A, Guerrero JM, Osuna C. Membrane-bound calmodulin in Xenopus laevis oocytes as a novel binding site for melatonin. FASEB J. 1998;12(13):1401–1408.
44. Hotta CT, Gazarini ML, Beraldo FH, et al. Calcium-dependent modulation by melatonin of the circadian rhythm in malarial parasites. Nat Cell Biol. 2000;2(7):466–468.
45. Srinivasan V, Ahmad AH, Mohamed M, Zakaria R. Melatonin effects on Plasmodium life cycle: new avenues for therapeutic approach. Recent Pat Endocr Metab Immune Drug Discov. 2012;6(2):139–147.
46. Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab. 2001;86(10):4727–4730.
47. Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med. 2004;116(2):91–95.
48. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24(11):1577–1601.
49. Pandi-Perumal SR, Trakht I, Spence DW, Srinivasan V, Dagan Y, Cardinali DP. The roles of melatonin and light in the pathophysiology and treatment of circadian rhythm sleep disorders. Nat Clin Pract Neurol. 2008;4(8):436–447.
50. Srinivasan V, Singh J, Pandi-Perumal SR, Brown GM, Spence DW, Cardinali DP. Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs. Adv Ther. 2010;27(11):796–813.
51. DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino JS Jr. The absolute bioavailability of oral melatonin. J Clin Pharmacol. 2000;40(7):781–784.
52. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005;9(1):11–24.
53. Arendt J. Does melatonin improve sleep? Efficacy of melatonin. BMJ. 2006;332(7540):550–553.
54. Hardeland R. New approaches in the management of insomnia: weighing the advantages of prolonged release melatonin and synthetic melatoninergic agonists. Neuropsych Dis Treat. 2009;5:341–354.
55. Miyamoto M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009;15(1):32–51.
56. de Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, Muñoz C, Millan MJ. Agomelatine, the first melatonergic antidepressant: discovery characterization and development. Nat Rev Drug Discov. 2010;9(8):628–642.
57. Lankford DA. Tasimelteon for insomnia. Expert Opin Invest Drugs. 2011;20(7):987–993.
58. Zemlan FP, Mulchahey JJ, Scharf MB, Mayleben DW, Rosenberg R, Lankford A. The efficacy and safety of the melatonin agonist β-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry. 2005;66(3): 384–390.
59. Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48(5):301–310.
60. McGechan A, Wellington K. Ramelteon. CNS Drugs. 2005;19(12): 1057–1065.
61. Miyamoto M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009;15(1):32–51.
62. Stevenson S, Bryson S, Amayke D, Hibberd M. Study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects. Clin Pharmacol Ther. 2004;75:22.
63. Cardinali DP, Srinivasan V, Brzezinski A, Brown GM. Melatonin and its analogs in insomnia and depression. J Pineal Res. 2012;52(4):365–375.
64. Pandi-Perumal SR, Srinivasan V, Spence DW, et al. Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther. 2009; 26(6):613–626.
65. Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP. Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. Nat Clin Pract Neurol. 2007;3(4):221–228.
66. Richardson GS, Zee PC, Wang-Weigand S, Rodriguez L, Peng X. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. J Clin Sleep Med. 2008;4(5):456–461.
67. Bellapart J, Boots R. Potential use of melatonin in sleep and delirium in the critically ill. Br J Anaesth. 2012;108(4):572–580.
68. Al-Aama T, Brymer C, Gutmanis I, Woolmore-Goodwin SM, Esbaugh J, Dasgupta M. Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial. Int J Geriatr Psych. 2011;26(7):687–694.
69. Ohta T, Murao K, Miyake K, Takemoto K. Melatonin receptor agonists for treating delirium in elderly patients with acute stroke. J Stroke Cerebrovasc Dis. 2013;22(7):1107–1110.
70. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306(3):954–964.
71. Racagni G, Riva MA, Molteni R, et al. Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. World J Biol Psychiatry. 2011;12(8):574–587.
72. Bertaina-Anglade V, La Rochelle CD, Boyer PA, Mocaer E. Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav Pharmacol. 2006;17(8):703–713.
73. Millan MJ. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther. 2006;110(2):135–370.
74. Bogaards JJ, Hissink EM, Briggs M, et al. Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling. Eur J Pharm Sci. 2000;12(2):117–124.
75. Dolder CR, Nelson M, Snider M. Agomelatine treatment of major depressive disorder. Ann Pharmacother. 2008;42(12):1822–1831.
76. Papp M, Litwa E, Gruca P, Mocaër E. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol. 2006;17(1):9–18.
77. Tabeeva GR, Sergeev AV, Gromova SA. [Possibilities of preventive treatment of migraine with MT1- and MT2 agonist and 5-HT2c receptor antagonist agomelatine (valdoxan)]. Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(9):32–36. Russian.
78. Rajaratnam SMW, Polymeropoulos MH, Fisher DM, et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet. 2009;373(9662):482–491.
79. Hardeland R. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders. Curr Opin Investig Drugs. 2009;10(7):691–701.
80. Vanda Pharma submits NDA for circadian regulator tasimelteon In totally blind. RTT News. May 31, 2011. Available from: http://archive.today/WzzaS.
81. Dhillon S, Clarke M. Tasimelteon: first global approval. Drugs. 2014;74(4):505–511.
82. Hardeland R. Investigational melatonin receptor agonists. Exp Opin Investig Drugs. 2010;19(6):747–764.
83. Hardeland R, Poeggeler B. Melatonin and synthetic melatonergic agonists: actions and metabolism in the central nervous system. Cent Nerv Syst Agents Med Chem. 2012;12(3):189–216.
84. Rivara S, Mor M, Bedini A, Spadoni G, Tarzia G. Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. Curr Top Med Chem. 2008;8(11):954–968.
85. Mulchahey JJ, Goldwater DR, Zemlan FP. A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin. Life Sci. 2004;75(15): 1843–1856.
86. Landolt HP, Wehrle R. Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood? Eur J Neurosci. 2009;29(9):1795–1809.
87. Sumaya IC, Masana MI, Dubocovich ML. The antidepressant-like effect of the melatonin receptor ligand luzindole in mice during forced swimming requires expression of MT2 but not MT1 melatonin receptors. J Pineal Res. 2005;39(2):170–177.
88. Li XM, Beau J, Delagrange P, Mocaër E, Lévi F. Circadian rhythm entrainment with melatonin, melatonin receptor antagonist S22153 or their combination in mice exposed to constant light. J Pineal Res. 2004;37(3):176–184.
89. Willis JL. The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson’s disease. Drug News Perspect. 2005;18(7):437–444.
90. Zlotos DP, Jockers R, Cecon E, Rivara S, Witt-Enderby PA. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014;57(8):3161–3185.
91. Tsotinis A, Gourgourinis J, Eleutheriades A, Davidson K, Sugden D. Design and synthesis of new N-OMe fluoro-indole melatoninergics. Med Chem. 2007;3(6):561–571.
92. Tsotinis A, Afroudakis PA, Davidson K, Prashar A, Sugden D. Design, synthesis, and melatoninergic activity of new azido- and isothiocyanato-substituted indoles. J Med Chem. 2007;50(25):6436–6440.
93. El Kazzouli S, Griffon du Bellay A, Berteina-Raboin S, Delagrange P, Caignard DH, Guillaumet G. Design and synthesis of 2-phenylimidazo[1,2-a]pyridines as a novel class of melatonin receptor ligands. Eur J Med Chem. 2011;46(9):4252–4257.
94. Koike T, Hoashi Y, Takai T, et al. 1,6-dihydro-2H-indeno[5,4-b]furan derivatives: design, synthesis, and pharmacological characterization of a novel class of highly potent MT2-selective agonists. J Med Chem. 2011;54(9):3436–3444.
95. Carocci A, Catalano A, Lovece A, et al. Design, synthesis, and pharmacological effects of structurally simple ligands for MT1 and MT2 melatonin receptors. Bioorg Med Chem. 2010;18(17):6496–6511.
96. Landagaray E, Ettaoussi M, Leclerc V, et al. New melatonin (MT1/MT2) ligands: fesign and synthesis of (8,9-dihydro-7H-furo[3,2-f]chromen-1-yl) derivatives. Bioorg Med Chem. 2014;22(3): 986–996.
97. Tsotinis A, Vlachou M, Papahatjis DP, et al. Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and N-acyl-5-methoxy-1-methyl-tryptamines. J Med Chem. 2006;49(12):3509–3519.
98. Dubocovich ML, Masana MI, Iacob S, Sauri DM. Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol. 1997;355(3):365–375.
99. Lucarini S, Bartolucci S, Bedini A, et al. Synthesis and configuration determination of all enantiopure stereoisomers of the melatonin receptor ligand 4-phenyl-2- propionamidotetralin using an expedient optical resolution of 4-phenyl-2-tetralone. Org Biomol Chem. 2012;10(2): 305–313.
100. Bedini A, Lucarini S, Spadoni G, et al. Toward the definition of stereochemical requirements for MT2-selective antagonists and partial agonists by studying 4-phenyl- 2-propionamidotetralin derivatives.J Med Chem. 2011;54(24):8362–8372.
101. Mésangeau C, Fraise M, Delagrange P, et al. Preparation and pharmacological evaluation of a novel series of 2-(phenylthio) benzo[b]thiophenes as selective MT2 receptor ligands. Eur J Med Chem. 2011;46(5):1835–1840.
102. Markl C, Clafshenkel WP, Attia MI, Sethi S, Witt-Enderby PA, Zlotos DP. N-acetyl-5-arylalkoxytryptamine analogs: probing the melatonin receptors for MT(1) -selectivity. Arch Pharm Chem Life Sci. 2011;334(10):666–674.
103. Spadoni G, Bedini A, Orlando P, et al. Bivalent ligand approach on N-{2-[(3-methoxyphenyl) methylamino]ethyl}-acetamide: synthesis, binding affinity and intrinsic activity for MT1 and MT2 melatonin receptors. Bioorg Med Chem. 2011;19(16):4910–4916.
104. Rivara S, Pala D, Lodola A, et al. MT1-selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation of N-{[(3-O-substituted)anilino]alkyl}amides. ChemMedChem. 2012;7(11):1954–1964.
105. Rawashdeh O, Maronde E. The hormonal Zeitgeber melatonin: role as a circadian modulator in memory processing. Front Mol Neurosci. 2012;5:27–33.
106. Bertaina-Anglade V, Drieu-La-Rochelle C, Mocaër E, Seguin L. Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat. Pharmacol Biochem Behav. 2011;98(4):511–517.
107. Gönenç S, Uysal N, Açikgöz O, Kayatekin BM, et al. Effects of melatonin on oxidative stress and spatial memory impairment induced by acute ethanol treatment in rats. Physiol Res. 2005;54(3):341–348.
108. Paulis L, Simko F, Laudon M. Cardiovascular effects of melatonin receptor agonists. Expert Opin Investig Drugs. 2012;21(11):1661–1678.
109. Laudon M, Urade Y, Huang Z. Neu-P11, a novel melatonin agonist: effects on sleep and EEG power spectra in rats. Sleep. 2008;31 (Suppl):A34–A35.
110. She M, Deng X, Guo Z, et al. Neu-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/high-sucrose-fed rats. Pharmacol Res. 2009;59(4):248–253.
111. Tian SW, Laudon M. Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models. Acta Pharmacol Sin. 2010;31(7):775–783.
112. He P, Ouyang X, Zhou S, et al. A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer’ disease. Horm Behav. 2013; 64(1):1–7.
113. Bustamante-García R, Lira-Rocha AS, Espejo-González O, Gómez-Martínez AE, Picazo O. Anxiolytic-like effects of a new 1-N substituted analog of melatonin in pinealectomized rats. Prog Neuropsychopharmacol Biol Psychiatry. 2014;51:133–139.
114. Mao L, Cheng Q, Guardiola-Lemaître B, et al. In vitro and in vivo antitumor activity of melatonin receptor agonists. J Pineal Res. 2010;49(3):210–221.
115. Ochoa-Sanchez R, Comai S, Lacoste B, et al. Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand. J Neurosci. 2011;31(50): 18439–18452.
116. Ochoa-Sanchez R, Rainer Q, Comai S, et al. Anxiolytic effects of the melatonin MT(2) receptor partial agonist UCM765: comparison with melatonin and diazepam. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(2):318–325.
117. Ochoa-Sanchez R, Comai S, Spadoni G, Bedini A, Tarzia G, Gobbi G. Melatonin, selective and non-selective MT1/MT2 receptors agonists: differential effects on the 24-h vigilance states. Neurosci Lett. 2014;561:156–161.
118. Schuck DC, Jordão AK, Nakabashi M, Cunha AC, Ferreira VF, Garcia CRS. Synthetic indole and melatonin derivatives exhibit antimalarial activity on the cell cycle of the human malaria parasite Plasmodium falciparum. Eur J Med Chem. 2014;78:375–382.
119. Carocci A, Catalano A, Bruno C, et al. N-(Phenoxyalkyl)amides as MT1 and MT2 ligands: Antioxidant properties and inhibition of Ca2+/CaM-dependent kinase II. Bioorg Med Chem. 2013;21(4): 847–851.
120. Peters JU. Polypharmacology – foe or friend? J Med Chem. 2013; 56(22):8955–8971.